title: Combination pharmacotherapy with incretins: what works best and when?
abstract: The incretin hormone glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors fill an unaddressed therapeutic gap in the treatment of type 2 diabetes mellitus (T2DM) by potentiating insulin secretion in pancreatic beta cells, suppressing glucagon secretion, delaying gastric emptying, and reducing appetite. The incretin therapies, alone or in combination with metformin and/or thiazolidinediones, yield improved glycemic control without risk of hypoglycemia and the potential for weight neutrality or even weight loss. New incretin-based approaches offer promising new strategies for treating T2DM by recruiting new, physiologically based mechanisms of action for glucoregulation in the context of a favorable safety profile.
authors.affiliation: MedStar Research Institute, 6495 New Hampshire Avenue, Suite 201, Hyattsville, MD 20783, USA.
authors.forename: Rebecca K
authors.initials: RK
authors.lastname: Over
authors.forename: Robert E
authors.initials: RE
authors.lastname: Ratner
mesh_terms: D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000627:therapeutic use; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D054795:Incretins / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D000069450:Liraglutide; D010455:Peptides / Q000627:therapeutic use; D018027:Receptors, Glucagon / Q000819:agonists; D016896:Treatment Outcome; D014688:Venoms / Q000627:therapeutic use
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D054795:Incretins; D007328:Insulin; D010455:Peptides; D018027:Receptors, Glucagon; D014688:Venoms; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide
references.citation: Diabetes Obes Metab. 2007 Mar;9(2):175-85
references.pmid: 17300593
references.citation: Am J Physiol Endocrinol Metab. 2004 Aug;287(2):E199-206
references.pmid: 15271645
references.citation: J Clin Endocrinol Metab. 2003 Jun;88(6):2719-25
references.pmid: 12788879
references.citation: Diabetes Care. 2006 Dec;29(12):2632-7
references.pmid: 17130196
references.citation: Diabetes. 2003 Feb;52(2):380-6
references.pmid: 12540611
references.citation: Diabetes Care. 2005 May;28(5):1092-100
references.pmid: 15855572
references.citation: Diabetologia. 1986 Jan;29(1):46-52
references.pmid: 3514343
references.citation: Diabetologia. 2007 Jun;50(6):1148-55
references.pmid: 17387446
references.citation: Endocrinology. 2003 Dec;144(12):5149-58
references.pmid: 12960095
references.citation: Endocrinology. 2003 Dec;144(12):5145-8
references.pmid: 14645210
references.citation: Diabetes Care. 2003 Oct;26(10):2929-40
references.pmid: 14514604
references.citation: J Clin Endocrinol Metab. 2005 Aug;90(8):4888-94
references.pmid: 15886245
references.citation: IDrugs. 2006 Aug;9(8):538-41
references.pmid: 16871459
references.citation: Diabetes Res Clin Pract. 2007 Apr;76(1):132-8
references.pmid: 17223217
references.citation: Diabetes Care. 2005 May;28(5):1083-91
references.pmid: 15855571
references.citation: Am J Physiol Endocrinol Metab. 2002 Oct;283(4):E745-52
references.pmid: 12217892
references.citation: Diabetes Care. 2004 Nov;27(11):2628-35
references.pmid: 15504997
references.citation: Horm Metab Res. 2004 Nov-Dec;36(11-12):761-5
references.pmid: 15655705
references.citation: Diabetes. 1998 Nov;47(11):1663-70
references.pmid: 9792533
references.citation: J Clin Endocrinol Metab. 2001 Aug;86(8):3717-23
references.pmid: 11502801
references.citation: Diabetes Care. 2004 Jun;27(6):1335-42
references.pmid: 15161785
references.citation: Endocr Pract. 2007 Sep;13(5):444-50
references.pmid: 17872344
references.citation: Diabetologia. 2006 Nov;49(11):2564-71
references.pmid: 17001471
references.citation: Endocrinology. 2004 Jun;145(6):2653-9
references.pmid: 15044356
references.citation: Am J Physiol. 1999 May;276(5):R1541-4
references.pmid: 10233049
references.citation: Ann Intern Med. 2007 Apr 3;146(7):477-85
references.pmid: 17404349
references.citation: Regul Pept. 1999 Nov 30;85(1):9-24
references.pmid: 10588446
references.citation: Diabetologia. 2005 Jul;48(7):1380-5
references.pmid: 15915337
references.citation: J Clin Endocrinol Metab. 2002 Mar;87(3):1239-46
references.pmid: 11889194
references.citation: Lancet. 2002 Mar 9;359(9309):824-30
references.pmid: 11897280
references.citation: N Engl J Med. 2008 May 1;358(18):1969-70; discussion 1971-2
references.pmid: 18450614
references.citation: Diabetes Care. 2007 Jun;30(6):1608-10
references.pmid: 17372153
references.citation: Diabetes Care. 2007 Jun;30(6):1487-93
references.pmid: 17353504
references.citation: J Clin Endocrinol Metab. 2004 May;89(5):2078-84
references.pmid: 15126524
references.citation: Diabetes Care. 2004 Dec;27(12):2874-80
references.pmid: 15562200
references.citation: Diabetes. 1989 Jul;38(7):902-5
references.pmid: 2661287
references.citation: Proc Natl Acad Sci U S A. 1987 May;84(10):3434-8
references.pmid: 3033647
references.citation: Eur J Pharmacol. 1996 Dec 30;318(2-3):429-35
references.pmid: 9016935
references.citation: Diabetes. 2004 May;53(5):1187-94
references.pmid: 15111485